深证成指、创业板指等指数的样本调整于今天（12月15日）正式实施，而上证50、科创50、中证A50等 指数的样本调整已于12月12日收市后正式生效。 根据此前公告，沪深300指数更换11只样本，华电新能、东山精密、指南针、胜宏科技等调入指数； 中证500指数更换50只样本，和而泰、华虹公司、东方雨虹、天合光能等调入指数； 中证1000指数更换100只样本，仕佳光子、永鼎股份、王府井、德科立等调入指数； 中证A50指数更换4只样本，华工科技、光启技术、中际旭创、胜宏科技等调入指数； 中证A100指数更换6只样本，东方财富、胜宏科技、中科曙光、赛力斯等调入指数； 中证A500指数更换20只样本，国泰海通、芯原股份、指南针等调入指数； 上证50指数更换4只样本，上汽集团、北方稀土、中科曙光等调入指数； 上证180指数更换7只样本，国投资本、中天科技、瑞芯微等调入指数； 科创50指数更换2只样本，翱捷科技、盛科通信等调入指数。 同时，根据深交所发布的关于调整深证成指、创业板指、深证100、创业板50等指数样本股的公告，深 证成指、创业板指、深证100、创业板50等指数样本股定期调整将于2025年12月15日正式生效。 ...

Group 1 - The sample adjustments for indices such as the Shenzhen Component Index and ChiNext Index will be officially implemented today, while adjustments for indices like the SSE 50 and STAR 50 have already taken effect after the market close on December 12 [1] - The CSI 300 Index will replace 11 samples, including Huadian New Energy, Dongshan Precision, and Guiding Compass [1] - The CSI 500 Index will replace 50 samples, with companies like Heertai, Huahong Semiconductor, and Dongfang Yuhong being added [1] - The CSI 1000 Index will replace 100 samples, including Shijia Photon, Yongding Co., and Wangfujing [1] - The CSI A50 Index will replace 4 samples, with Huagong Technology and Guangqi Technology being included [1] - The CSI A100 Index will replace 6 samples, including Dongfang Fortune and Silex [1] - The CSI A500 Index will replace 20 samples, with Guotai Haitong and Chipone being added [1] - The SSE 50 Index will replace 4 samples, including SAIC Motor and Northern Rare Earth [1] - The SSE 180 Index will replace 7 samples, with Guotai Junan and Zhongtian Technology being included [1] - The SSE 380 Index will replace 38 samples, including COSCO Shipping Energy and Jinfat Technology [1] - The STAR 50 Index will replace 2 samples, with Aojie Technology and Shengke Communication being added [1] Group 2 - The Shenzhen Stock Exchange announced that the sample adjustments for the Shenzhen Component Index, ChiNext Index, Shenzhen 100, and ChiNext 50 will officially take effect on December 15, 2025 [2] - The Shenzhen Component Index will replace 17 samples, including Shenzhen Housing A and Demingli [2] - The ChiNext Index will replace 8 samples, with Shuanglin Co. and Changxin Bochuang being added [3] - The Shenzhen 100 Index will replace 7 samples, including Cangge Mining and Guohang Aviation [4] - The ChiNext 50 Index will replace 5 samples, with companies like Changshan Pharmaceutical and Feili Hua being included [5]

Core Viewpoint - Haohai Biology is expanding its business by acquiring a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membrane, despite Ruiji's ongoing financial losses and lack of performance guarantees in the transaction [1][3]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been struggling with losses of 11.77 million yuan last year and 11.29 million yuan in the first three quarters of this year [1][2]. - The transaction does not grant Haohai Biology control over Ruiji's existing team or decision-making on financial and operational matters, as the stake does not allow for consolidation in Haohai's financial reports [2]. Group 2: Financial Performance of Haohai Biology - Haohai Biology's core business has been under pressure, with a revenue decline of 7.12% and a net profit drop of 10.29% in the first half of this year compared to the previous year [1][5]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan last year, with growth rates slowing significantly [5]. - In the first three quarters of this year, Haohai's revenue was 1.899 billion yuan, down 8.47%, and net profit was 305 million yuan, down 10.63% [7]. Group 3: Market Context and Competition - The global amniotic membrane market is projected to grow from over 1.89 billion dollars last year to 3.97 billion dollars by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9]. - Analysts suggest that while the acquisition may provide strategic benefits, the ongoing losses and competitive landscape present significant challenges for Haohai Biology [9].

Group 1: Retail and Service Industry Insights - The report highlights a recovery in the hotel and duty-free sectors, suggesting that the hotel prices have gradually increased since the second half of this year, with a recommendation to focus on hotel stocks such as Huazhu Group, Jinjiang Hotels, and ShouLai Hotels [6][12][17] - Duty-free sales are showing signs of bottoming out, with new policies implemented to expand the range of duty-free products and eligible consumers, leading to a significant increase in sales figures [12][15][16] - The report emphasizes the importance of service consumption policies, particularly in the context of the ice and snow economy, silver-haired economy, and sports events, recommending investments in companies like Changbai Mountain and Sanchuan Tourism [26][28][29] Group 2: AI Applications in Various Industries - The report discusses the acceleration of AI applications in the education and human resources sectors, with companies like Keri International and Beijing Renli leveraging AI to enhance recruitment efficiency [39][44] - AI's integration into 3D printing and e-commerce is highlighted, with a focus on companies like Huina Technology and Xiaogoods City, which are expected to benefit from cost reductions through full-chain penetration [6][39] - The report notes that AI applications are driving significant changes in operational efficiency and commercial opportunities across various sectors, particularly in human resources [39][44] Group 3: Beauty and Personal Care Sector - The beauty and personal care industry is experiencing a mild recovery, with domestic brands showing strong performance during the Double Eleven shopping festival, indicating a shift in competitive dynamics [6][32] - The report identifies key players in the beauty sector, recommending brands like Mao Ge Ping and Shanghai Jahwa, while also suggesting a focus on high-growth segments within the industry [6][32] - The medical beauty sector is under pressure but is seeing consolidation and innovation, with recommendations for companies like Jinbo Biological and Kedi-B [6][32] Group 4: Jewelry and Precious Metals - The jewelry sector is undergoing a transformation, with a focus on overseas expansion as a second growth curve, recommending companies like Laopu Gold and Chaohongji [6][32] - The report emphasizes the importance of high-value jewelry products and the impact of new tax regulations on the market dynamics [6][32] Group 5: Food and Beverage Industry - The food and beverage sector is witnessing a shift, with a focus on leading brands expanding their store counts and product categories, particularly in the tea and dining segments [32][38] - The report highlights the competitive landscape in the restaurant industry, noting the resilience of Western fast food and the growth of Chinese casual dining brands [32][38]

Investment Rating - The report indicates a weak performance in the cosmetics and medical beauty sector, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [3][4]. Core Insights - The cosmetics sector faced pressure in November, with overall GMV in the Taobao system showing weakness due to the pre-promotion of the Double 11 sales event and the rise of Douyin as a sales channel. Brands like Han Shu and Lin Qingxuan maintained stable GMV, while others like Feicui continued to grow significantly [3][9]. - The collagen medical beauty segment is expanding, with two new animal-derived collagen products approved for market entry, expected to drive growth in this area [3][9]. - The report highlights the leading market share of Minoxidil products from Mandi International in the hair loss treatment market, with a steady revenue growth from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% from 2022 to 2024 [10][11]. - L'Oréal's acquisition of an additional 10% stake in Galderma, raising its total ownership to 20%, signifies a strategic shift towards the medical beauty and skin health sectors, aiming to adapt to the slowing growth in the Chinese beauty market [3][18]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index and its sub-indices for cosmetics and personal care products have shown declines of 1.2% and 1.7%, respectively, indicating underperformance compared to the Shenwan A Index [4][6]. Key Market Developments - The overall GMV for cosmetics in November was weak, influenced by earlier sales spikes in October and competition from Douyin [9]. - The approval of new collagen products is expected to enhance the supply side of the medical beauty market, with projections for continued expansion in 2026 [9][22]. Company Highlights - Mandi International has maintained a dominant position in the Minoxidil market, with its products accounting for approximately 57% and 71% of the market share in the hair loss treatment and Minoxidil categories, respectively, as of 2024 [11][13]. - The report notes that the Chinese consumer healthcare market is projected to grow from 931.3 billion yuan in 2018 to 16.42 trillion yuan by 2024, with significant growth in hair health and skin health segments [12][13].

Core Viewpoint - Haohai Biology has acquired a 19.8% stake in Jiangxi Ruiji Biological Engineering Technology Co., Ltd. for 38.35 million yuan, aiming to enter the high-value medical device sector of biological amniotic membranes, despite Ruiji's ongoing financial struggles and lack of performance guarantees in the transaction [1][4]. Group 1: Acquisition Details - The acquisition involves Haohai Biology purchasing 8.4661 million shares of Ruiji, which has been facing financial difficulties with losses of 11.77 million yuan in 2024 and 11.29 million yuan in the first nine months of 2025 [1][3]. - The transaction does not include any performance commitments or earn-out arrangements, posing a risk of investment loss if Ruiji's performance declines further [4]. Group 2: Haohai Biology's Business Context - Haohai Biology, the first biopharmaceutical company listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, has seen a decline in its core business, with revenue and net profit dropping by 7.12% and 10.29% respectively in the first half of 2025 [1][6]. - The company reported a revenue of 2.698 billion yuan and a net profit of 420 million yuan in 2024, but growth has stagnated, with significant declines in its medical aesthetics, ophthalmology, and orthopedics segments [6][7]. Group 3: Market Potential and Competition - The global amniotic membrane market is projected to grow from 1.89 billion USD in 2024 to 3.97 billion USD by 2034, with a compound annual growth rate of approximately 7.7% [8]. - Competition in the biological amniotic membrane sector is intensifying, with other companies like Guangzhou Ruitai Biological and Chengdu Qingshan Likang Pharmaceutical also entering the market [9].

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, despite recent underperformance compared to the market [3][4]. Core Insights - The cosmetics and medical beauty sector has shown weaker performance, with the Shenwan Beauty Care Index declining by 1.6% from December 5 to December 12, 2025, underperforming the market [4][5]. - The report highlights that the November sales in the cosmetics sector were impacted by pre-Double 11 promotions and the rise of Douyin as a sales channel, leading to a weaker overall GMV [4][10]. - The collagen medical beauty segment is expanding, with two new animal-sourced collagen products approved for market, indicating growth potential in this area [4][10]. - The report emphasizes the strong market position of Mandi International in the minoxidil hair growth market, with a revenue increase from 982 million yuan in 2022 to approximately 1.455 billion yuan in 2024, reflecting a CAGR of 21.7% [4][11][12]. - L'Oréal's recent acquisition of an additional 10% stake in Galderma signifies a strategic shift towards medical aesthetics and skin health, aiming to adapt to the slowing growth in the Chinese beauty market [4][21]. Summary by Sections Industry Performance - The Shenwan Beauty Care Index decreased by 1.6%, with the Shenwan Cosmetics Index down by 1.2% and the Shenwan Personal Care Index down by 1.7% during the specified period [4][5]. - Notable stock performances included Water Sheep Co. (+5.9%) and Jinsong New Materials (+4.3%), while Hongmian Co. (-10.6%) and Juzhi Biological (-8.4%) faced significant declines [7]. Market Trends - The overall GMV for cosmetics in November was weak, influenced by the earlier sales surge in October and the emergence of Douyin as a competitive sales platform [4][10]. - The report notes that brands like Han Shu and Lin Qingxuan maintained stable GMV, while brands like Feicui continued to experience high growth [4][10]. Company Highlights - Mandi International has established a leading position in the minoxidil market, with a market share of approximately 57% in the hair loss treatment sector and 71% in the minoxidil product market as of 2024 [4][15]. - The company has shown consistent revenue growth, with a net profit increase from 2022 to the first half of 2025, indicating a robust business model [4][12][15]. Investment Recommendations - The report recommends focusing on companies with strong product lines and high profitability in the medical beauty sector, such as Ai Meike, while also suggesting attention to companies like Langzi Co. and Ru Yi Chen [4][10].

Core Viewpoint - Huaxi Biological, a leading player in the medical beauty industry, is currently facing significant challenges as the hyaluronic acid market experiences diminishing returns, leading to a decline in revenue and profit [3][5]. Group 1: Financial Performance - In the first three quarters of this year, Huaxi Biological's revenue decreased by 18.36% to 3.163 billion yuan, while net profit attributable to shareholders fell by 30.29% to 252 million yuan [5]. - As of December 5, Huaxi Biological's stock closed at 45.57 yuan, below its IPO price of 47.79 yuan, with a market capitalization of only 22 billion yuan, a drop from its peak of 140 billion yuan [5]. - By the third quarter of 2025, the company's revenue was 903 million yuan, down 15.16%, while net profit attributable to shareholders increased by 55.63% to 32 million yuan [14]. Group 2: Product and Brand Strategy - Huaxi Biological's skincare products, primarily based on hyaluronic acid, have seen a significant revenue decline, with a 33.97% drop in the first half of 2025, contributing to 40.36% of the company's main business revenue [9]. - The company has decided to eliminate several underperforming sub-brands, including Runxihe, Runxiquan, and Demarun, in an effort to focus on its core brands [9][11]. - The revenue from core brands like Kuadi and Runbaiyan has also shown signs of fatigue, with both brands expected to fall below the 1 billion yuan revenue mark by 2024 [10][17]. Group 3: Market Dynamics - The cosmetic market is experiencing intense competition, with a significant increase in the number of hyaluronic acid products, leading to market saturation and reduced consumer interest [16]. - The price war in the hyaluronic acid sector has intensified, with products like Joia's hyaluronic acid being sold at drastically reduced prices, marking the end of high-profit margins in the industry [17]. - The overall market for functional skincare products is projected to reach 211.8 billion yuan by 2025, with collagen expected to surpass hyaluronic acid as the leading ingredient [21]. Group 4: Future Outlook - Huaxi Biological is undergoing a transformation, shifting its focus from skincare to new areas such as weight loss and small nucleic acid drugs, investing 138 million yuan in a strategic partnership with Saint Pharma [24]. - The company is rebranding its skincare product line to emphasize technological innovation, indicating a shift in strategy to adapt to changing market conditions [24].

Core Viewpoint - The A-share market has 47 stocks involved in the cosmetics industry chain, with 18 stocks reporting year-on-year growth in net profit for the first three quarters, indicating a positive trend in the sector [1] Group 1: Performance Overview - 18 stocks achieved year-on-year growth in net profit, with a success rate of approximately 41.67% [1] - Among the stocks with profit growth, Fujilai, Qingsong Co., and Xianggang Technology reported significant increases in net profit, with growth rates of 430.16%, 246.98%, and 186.19% respectively [1] Group 2: Research and Development Investment - The majority of the stocks with profit growth focus on R&D investment, with 12 out of the 18 stocks increasing their R&D expenses in the first three quarters [1] - Xianggang Technology, Ruoyuchen, and Shuiyang Co. had R&D expense growth rates exceeding 30% [1] Group 3: Capital Flow - 16 stocks have received net financing inflows since December, indicating strong investor interest [1] - Lihua Science and Technology, Aimeike, and Zhongyuan Qihe led in net financing inflows, with amounts reaching 58.53 million, 48.75 million, and 44.02 million respectively [1]

证券日报网讯 12月11日，爱美客在互动平台回答投资者提问时表示，截至2025年12月10日，公司股东 人数为60403户。 （文章来源：证券日报） ...